Bristol-Myers Squibb Enters 3-Year Agreement with Reckitt Benckiser Group for Over-the-Counter Medicines

Bristol-Myers Squibb Company BMY today announced it has entered into a three-year collaboration agreement with Reckitt Benckiser Group plc RBGLY for several of its over-the-counter medicines currently sold across Latin America, primarily in Mexico and Brazil. Under the terms of the collaboration agreement, Reckitt Benckiser will pay Bristol-Myers Squibb an upfront payment in the amount of $438 million for the exclusive rights to sell, distribute and market the following medicines for a three-year period: Picot, an antacid, Tempra, a pain reliever and fever reducer, Micostatin, an antifungal, and Graneodin, a cough and cold medicine, sold primarily in Mexico; and Dermodex, an anti-rash cream, Luftal, an anti-gas medicine, and See full press release